Assessment of the Effects and Tolerability of RD03/2016 (Levofloxacin; Ketorolac Trometamol 0.5+0.5% w/v Eye Drops Solution) for the Treatment of Bacterial Conjunctivitis in Adults: a Multicentre, Randomized, Blinded-assessor, Phase II Non Inferiority Study - MIRAKLE
Latest Information Update: 07 Oct 2024
At a glance
- Drugs Ketorolac/trometamol (Primary) ; Levofloxacin (Primary) ; RD03/2016 (Primary)
- Indications Conjunctivitis
- Focus Therapeutic Use
- Acronyms MIRAKLE
- 07 Oct 2024 New trial record